Business Wire

Permasteelisa Group to Join Grandland

Jaa

Worldwide leading contractor in engineering, project management, manufacturing and installation of architectural envelopes and interior systems, Permasteelisa Group, will join forces with Grandland Group – a fast growing, Shenzhen-based specialist in design and construction of architectural decoration. The strategic alliance will create the biggest, most comprehensive curtain wall player in the world, with exceptional potential for further growth for both companies. Permasteelisa will remain fully committed to build avant-garde architectures and top end, high-quality projects which have become its trademark.

The news comes today after LIXIL Group Corporation (LIXIL Group) (TOKYO: 5938) – a global leader in the housing and building industry – announced that it has decided to sell 100% of shares of Permasteelisa S.p.A., held by its major subsidiary LIXIL Corporation, to Grandland Holdings Group Limited (Grandland) for a base sale price of EUR 467 million.

The transaction is subject to customary closing conditions and regulatory approvals including in China, the United States and Russia. Permasteelisa will be managed as a separate business entity and its independence will be guaranteed by the new shareholder. Permasteelisa’s headquarters will continue to be based in Vittorio Veneto, Italy, where they have been since the incorporation of the company.

Known for its iconic, special features buildings, such as the Shard in London, the Apple Park, Apple’s new HQs in Cupertino, the Sydney Opera House and the International Commerce Centre in Hong Kong, Permasteelisa works worldwide to turn the visions of the best architects into reality, and has a history full of symbolic buildings that have changed the skylines around the world.

Permasteelisa Group has an annual turnover of approximately € 1.4 billion.

Combining Permasteelisa’s position as a premium leader in the market and its scale across EMEA, North and South America as well as parts of Asia, along with Grandland’s industrial integration capabilities and strength in China, will create an even a bigger player in the curtain wall segment globally,” states Riccardo Mollo, Chief Executive Officer of Permasteelisa Group. “While Permasteelisa will maintain its operating independence, the opportunities for operating synergies with Grandland are tremendous.”

As part of the agreement, Mr. Mollo has been confirmed by the new shareholder in his role as CEO, and the rest of the top management have also been confirmed to retain their positions. These decisions allow Permasteelisa Group to spearhead future growth by reinforcing the passion for quality which has always been the distinctive trademark of the company.

Grandland is a high-quality, service-oriented architectural decoration enterprise that ranks #1 in South China, thanks to a fast-growing business portfolio. Based in Shenzhen, it generated sales of RMB 10.86 billion in 2016 and ranks among the top 500 Chinese brands under the architectural decoration category that influence the world. The company has recognized the superior reputation of Permasteelisa in setting the standard for the curtain wall industry due to its vision and commitment to state-of-the-art and high-tech products. The operations and footprints of both companies are complementary:

  • The transaction will allow Grandland to differentiate its offering in the crowded and competitive curtain wall market, by leveraging Permasteelisa’s world-wide positioning as a premium market leader with a history of shaping some of the world’s most iconic skylines;
  • Synergies with Grandland will create unique potential for Permasteelisa to better serve the entire Asian region;
  • Grandland’s focus on the interior business will complement Permasteelisa offering in the niche.

I am pleased that Grandland has acknowledged and embraced our business strategy. Upon completion of the transaction, we expect Permasteelisa to complete its ongoing turnaround process, while the journey to increased levels of solidity will continue,” Mr Mollo added. “We are also grateful to LIXIL for their support throughout the years and the way they handled the transition.”

About Permasteelisa Group

Permasteelisa Group is a worldwide leading Contractor in engineering, project management, manufacturing and installation of architectural envelopes and interior systems. The Group brings its Know-How and expertise to all projects, in particular when dealing with Special Features Buildings, beginning with the design development phases all the way to the successful completion, achieving the customer's expectations.

Today, Permasteelisa is a global integrated Group present in four continents with a network of over 50 companies in more than 30 countries, generating a total turnover of around 1.4 billion euro a year. The Group employs more than 6,500 people worldwide in its Engineering & Design centres and in the 10 manufacturing plants equipped with the most modern and advanced technologies.

The mission of the Permasteelisa Group is to design and build innovative and avant-garde architectural works alongside the world’s greatest in contemporary architecture, by using advanced technologies and eco-sustainable solutions. The quality of our architectural envelopes and interiors is guaranteed by our rigorous quality control system. Besides, it's constantly improved through R&D in new design and construction technologies and through the use of innovative materials. The use of environmentally friendly materials and eco-sustainable processes, as well as our commitment in energy saving, protect the environment and make the buildings themselves more comfortable and efficient.

Among Permasteelisa Group's projects are some world-renowned contemporary architectural works, such as the Sydney Opera House (the first building to make extensive use of the curtain walls), the Eight Spruce Street (a.k.a. Beekman Tower) in NYC, The Shard and 20 Fenchurch Street in London, the revolutionary Guggenheim Museum in Bilbao, the extraordinary Walt Disney Concert Hall in Los Angeles and the Museum of Modern Art in New York.

About Grandland

Grandland Holdings is the parent company of Grandland Group (SHZ: 002482), which is one of the leading companies specializing in design and construction of architectural decoration in China, the company provides a one-stop architectural decoration service to clients in curtain walls, landscape, connected devices, mechatronics, fire control, air-conditioning and water heating. Grandland serves every major developer in China, and the Evergrande Group is a key strategic partner of Grandland. Grandland Holdings had sales of RMB10.86 billion in 2016 and the company recognized as Top 500 Chinese brands (under architectural decoration category) that influence the World. Grandland's headquarters are in Shenzhen, China. Further information about Grandland Holdings is available at www.gtholdings.cn.

Contact information

Permasteelisa Group
Massimiliano Fanzaga, +39 347 958 3056
Head of Communication Permasteelisa S.p.A.
m.fanzaga@permasteelisagroup.com
or
Edelman
Mauro Turcatti, +39 340 832 6620
mauro.turcatti@edelman.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00Tiedote

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10Tiedote

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13Tiedote

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00Tiedote

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41Tiedote

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00Tiedote

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme